by barry101 | Dec 20, 2023 | Press Releases
HOUSTON, Dec. 20, 2023 — Moleculin Biotech, Inc. (NASDAQ: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced that it has entered into a...
by barry101 | Dec 11, 2023 | Press Releases
– CR rate of 36% in Intent to Treat or ITT (n=11) subjects with durability – CR rate of 44% in subjects treated with Annamycin (n=9) – Durability of CR’s up to 8 months & climbing (no relapses to date) – Recruitment in MB-106 Phase...
by barry101 | Nov 13, 2023 | Press Releases
– MB-106: CR rate of 38% (N=8) with durability up to 8 months – Builds on CRi rate of 60% in MB-105 monotherapy AML trial last cohort (N=5) – MB-107: Phase 1B median extended overall survival of 11 months for heavily pre-treated subjects (N=15)...
by barry101 | Nov 13, 2023 | Press Releases
– MB-106: CR rate of 38% (N=8) with durability up to 8 months – Builds on CRi rate of 60% in MB-105 monotherapy AML trial last cohort (N=5) – MB-107: Phase 1B median extended overall survival of 11 months for heavily pre-treated subjects (N=15)...
by barry101 | Nov 13, 2023 | Press Releases
– Ends Quarter with $24.6 million in Cash with Runway Estimated into Third Quarter of 2024 – Third quarter marked by additional positive clinical data from Annamycin lead development programs – Growing body of Annamycin efficacy and safety clinical...
